Life sciences executive to aid governance and financial planning as company continues growth initiatives
Harvard Bioscience, Inc. has made the appointment of Stephen DeNelsky to its Board of Directors effective September 5, 2025. DeNelsky will also be a member of the Board’s Nominating and Governance Committee.
President & CEO John Duke greeted the appointment, praising DeNelsky’s extensive life sciences financial strategy and corporate governance experience. “His experience in our sectors of operation and his history of shepherding life sciences companies will be extremely beneficial as we look to the future,” Duke stated.
DeNelsky expressed enthusiasm for the role, stating: “I’m honored to join the Board and look forward to contributing to strong governance and long-term value creation at Harvard Bioscience.”
